NuCana Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

NuCana wird ein Gewinn- und Umsatzwachstum von 44.9% bzw. 75.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 42.9% pro Jahr wachsen soll.

Wichtige Informationen

44.9%

Wachstumsrate der Gewinne

42.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.7%
Wachstumsrate der Einnahmen	75.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	17 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:NCNA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (GBP Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2	-28	N/A	N/A	4
12/31/2025	1	-25	N/A	N/A	4
12/31/2024	N/A	-26	N/A	N/A	4
3/31/2024	N/A	-27	-22	-22	N/A
12/31/2023	N/A	-28	-27	-26	N/A
9/30/2023	N/A	-35	-34	-33	N/A
6/30/2023	N/A	-33	-22	-22	N/A
3/31/2023	N/A	-31	-25	-25	N/A
12/31/2022	N/A	-32	-24	-23	N/A
9/30/2022	N/A	-30	-27	-26	N/A
6/30/2022	N/A	-34	-30	-29	N/A
3/31/2022	N/A	-39	-25	-24	N/A
12/31/2021	N/A	-41	-25	-24	N/A
9/30/2021	N/A	-39	-23	-23	N/A
6/30/2021	N/A	-40	-28	-27	N/A
3/31/2021	N/A	-36	-25	-23	N/A
12/31/2020	N/A	-31	-23	-22	N/A
9/30/2020	N/A	-26	-18	-17	N/A
6/30/2020	N/A	-22	-21	-20	N/A
3/31/2020	N/A	-20	-25	-24	N/A
12/31/2019	N/A	-21	-25	-24	N/A
9/30/2019	N/A	-17	-24	-22	N/A
6/30/2019	N/A	-16	-19	-18	N/A
3/31/2019	N/A	-13	-17	-16	N/A
12/31/2018	N/A	-14	-14	-12	N/A
9/30/2018	N/A	-15	-14	-13	N/A
6/30/2018	N/A	-26	-12	-11	N/A
3/31/2018	N/A	-28	-11	-10	N/A
12/31/2017	N/A	-23	N/A	-9	N/A
9/30/2017	N/A	-20	N/A	-8	N/A
6/30/2017	N/A	-7	N/A	-8	N/A
3/31/2017	N/A	-6	N/A	-9	N/A
12/31/2016	N/A	-6	N/A	-9	N/A
12/31/2015	N/A	-5	N/A	-4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NCNA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: NCNA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: NCNA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: NCNADie Einnahmen des Unternehmens (75.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: NCNADie Einnahmen des Unternehmens (75.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von NCNA in 3 Jahren voraussichtlich hoch sein wird

NuCana Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 9.5% to US$4.79

Price target increased by 10% to US$4.38

Price target decreased to US$3.42

Price target decreased to US$4.26

Price target decreased to US$4.26

Price target decreased to US$4.69

Recent updates

New minor risk - Shareholder dilution

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Price target increased by 9.5% to US$4.79

Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely

Insufficient new directors

New major risk - Financial position

New major risk - Revenue and earnings growth

New major risk - Share price stability

Nucana plc Announces Presentation on Ongoing Nutide:701 Study of Nuc-7738 At the Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics 2023

We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate

NuCana plc Presents Encouraging Data on NUC-3373 in Colorectal Cancer At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Here's Why We're A Bit Worried About NuCana's (NASDAQ:NCNA) Cash Burn Situation

NuCana plc, Annual General Meeting, Jun 15, 2023

NuCana Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Price target increased by 10% to US$4.38

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Price target decreased to US$3.42

Price target decreased to US$4.26

NuCana plc Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Price target decreased to US$4.26

NuCana: An Intriguing 'Sum Of The Parts' Story

Nucana Presents Promising Data on NUC-7738 At the European Society of Medical Oncology (Esmo) Annual Meeting 2022

NuCana GAAP EPS of -£0.07

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

NuCana regains Nasdaq compliance

NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead

Price target decreased to US$4.69

NuCana Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Less than half of directors are independent

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Price target decreased to US$9.00

Price target decreased to US$11.67

NuCana Announces Update for Phase 3 Biliary Tract Cancer Study

NuCana plc Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study

We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth

NuCana: Preparing For A Critical 2022

Price target increased to US$17.25

We're Interested To See How NuCana (NASDAQ:NCNA) Uses Its Cash Hoard To Grow

NuCana: The Market Continues To Overlook Its ProTide Platform Technology

We Think NuCana (NASDAQ:NCNA) Can Afford To Drive Business Growth

Forecast to breakeven in 2025

New 90-day low: US$4.38

Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth

NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer

New 90-day high: US$6.40

New 90-day low: US$4.40

NuCana plc Appoints Andrew Kay as Chairman of its Board of Directors

How Many NuCana plc (NASDAQ:NCNA) Shares Do Institutions Own?

Price target lowered to US$17.29

NuCana (NCNA) Investor Presentation - Slideshow

Nucana plc Announces Final Data from the Phase Ib Study of Acelarin Plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in the Oncologist

Price target raised to US$19.00

NuCana reports Q3 results

New 90-day low: US$4.45

NuCana plc Announces the Appointment of Bali Muralidhar, M.D., Ph.D. to Its Board of Directors

NuCana plc Announces Data from Ongoing NUC-3373, NUC-7738 and Acelarin Phase III Study

New 90-day low: US$4.58

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken